CURANEX PHARMACEUTICALS INC (CURX) Fundamental Analysis & Valuation

NASDAQ:CURX • US23126K1060

Current stock price

0.457 USD
+0.01 (+2.28%)
Last:

This CURX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CURX Profitability Analysis

1.1 Basic Checks

  • In the past year CURX has reported negative net income.
  • CURX had a negative operating cash flow in the past year.
CURX Yearly Net Income VS EBIT VS OCF VS FCFCURX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 0 -2M -4M -6M -8M -10M

1.2 Ratios

  • With a Return On Assets value of -36.49%, CURX perfoms like the industry average, outperforming 43.98% of the companies in the same industry.
  • With a decent Return On Equity value of -37.66%, CURX is doing good in the industry, outperforming 60.21% of the companies in the same industry.
Industry RankSector Rank
ROA -36.49%
ROE -37.66%
ROIC N/A
ROA(3y)-44.03%
ROA(5y)N/A
ROE(3y)-47.14%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CURX Yearly ROA, ROE, ROICCURX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CURX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CURX Yearly Profit, Operating, Gross MarginsCURX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025 0 -20 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CURX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, CURX has more shares outstanding
  • There is no outstanding debt for CURX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CURX Yearly Shares OutstandingCURX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 5M 10M 15M 20M 25M
CURX Yearly Total Debt VS Total AssetsCURX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • CURX has an Altman-Z score of 20.42. This indicates that CURX is financially healthy and has little risk of bankruptcy at the moment.
  • CURX has a Altman-Z score of 20.42. This is amongst the best in the industry. CURX outperforms 89.53% of its industry peers.
  • CURX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.42
ROIC/WACCN/A
WACCN/A
CURX Yearly LT Debt VS Equity VS FCFCURX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 5M -5M 10M -10M

2.3 Liquidity

  • CURX has a Current Ratio of 81.95. This indicates that CURX is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of CURX (81.95) is better than 100.00% of its industry peers.
  • A Quick Ratio of 81.95 indicates that CURX has no problem at all paying its short term obligations.
  • CURX's Quick ratio of 81.95 is amongst the best of the industry. CURX outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 81.95
Quick Ratio 81.95
CURX Yearly Current Assets VS Current LiabilitesCURX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. CURX Growth Analysis

3.1 Past

  • The earnings per share for CURX have decreased strongly by -1174.62% in the last year.
EPS 1Y (TTM)-1174.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-733.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CURX Yearly Revenue VS EstimatesCURX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 5K 10K 15K 20K 25K

More info and screens

Find the best growth stocksShow best growing peers

0

4. CURX Valuation Analysis

4.1 Price/Earnings Ratio

  • CURX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CURX Price Earnings VS Forward Price EarningsCURX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CURX Per share dataCURX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CURX Dividend Analysis

5.1 Amount

  • CURX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CURX Fundamentals: All Metrics, Ratios and Statistics

CURANEX PHARMACEUTICALS INC

NASDAQ:CURX (4/17/2026, 11:55:58 AM)

0.457

+0.01 (+2.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners1.5%
Inst Owner Change0%
Ins Owners67.76%
Ins Owner Change0%
Market Cap12.96M
Revenue(TTM)N/A
Net Income(TTM)-4.23M
AnalystsN/A
Price TargetN/A
Short Float %1.17%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.16
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -36.49%
ROE -37.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.03%
ROA(5y)N/A
ROE(3y)-47.14%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 81.95
Quick Ratio 81.95
Altman-Z 20.42
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1174.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-733.08%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1359.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1787.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1787.06%
OCF growth 3YN/A
OCF growth 5YN/A

CURANEX PHARMACEUTICALS INC / CURX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CURANEX PHARMACEUTICALS INC (CURX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to CURX.


What is the valuation status of CURANEX PHARMACEUTICALS INC (CURX) stock?

ChartMill assigns a valuation rating of 0 / 10 to CURANEX PHARMACEUTICALS INC (CURX). This can be considered as Overvalued.


What is the profitability of CURX stock?

CURANEX PHARMACEUTICALS INC (CURX) has a profitability rating of 1 / 10.